阿折地平
阿折地平结构式
|
常用名 | 阿折地平 | 英文名 | Azelnidipine |
|---|---|---|---|---|
| CAS号 | 123524-52-7 | 分子量 | 582.646 | |
| 密度 | 1.3±0.1 g/cm3 | 沸点 | 709.3±60.0 °C at 760 mmHg | |
| 分子式 | C33H34N4O6 | 熔点 | 120-126ºC | |
| MSDS | 中文版 美版 | 闪点 | 382.8±32.9 °C | |
| 符号 |
GHS05, GHS07 |
信号词 | Danger |
|
Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
Tohoku J. Exp. Med. 228 , 305-315, (2012) Many studies have aimed to identify anti-atherogenic agents in cardiovascular medicine. We have recently demonstrated that the combination therapy with olmesartan (OLM), an angiotensin II receptor blocker, and azelnidipine (AZL), a dihydroprydine calcium-chan... |
|
|
The pharmacological differences in antianginal effects of long-lasting calcium channel blockers: azelnidipine and amlodipine.
J. Cardiovasc. Pharmacol. 61(1) , 63-9, (2013) We examined antianginal effects of azelnidipine and amlodipine in an arginine vasopressin-induced rat anginal model. Oral administration of azelnidipine or amlodipine produced long lasting inhibition of arginine vasopressin-induced ST-segment depression in el... |
|
|
Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis.
Cardiovasc. Diabetol. 10 , 97, (2011) Numerous evidences suggest that diabetic heart is characterized by compromised ventricular contraction and prolonged relaxation attributable to multiple causative factors including calcium accumulation, oxidative stress and apoptosis. Therapeutic intervention... |
|
|
Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT).
Cardiovasc. Diabetol. 10 , 79, (2011) Hypertension is associated with impaired glucose tolerance and insulin resistance. Medical treatment that interferes with various steps in the renin-angiotensin system improves glucose tolerance and insulin resistance. However, it remains unclear if long-acti... |
|
|
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Hypertens. Res. 34(8) , 935-41, (2011) The present study aimed to determine whether either of two calcium channel blockers affected urinary albumin excretion or urinary levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG) and liver-type fatty acid-binding protein (L-FABP) in hypertensive diabetic patien... |
|
|
Vasorelaxation induced by new third-generation dihydropyridine calcium antagonist azelnidipine in human internal mammary artery.
Ann. Thorac. Surg. 96(4) , 1316-21, (2013) Graft spasm remains challenging in coronary artery bypass graft (CABG) surgery. Calcium antagonists are commonly used in patients with coronary artery disease. We investigated the inhibitory effect of the new third-generation dihydropyridine calcium antagonis... |
|
|
Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.
Hypertens. Res. 35(3) , 348-55, (2012) Dihydropyridine-type calcium channel blockers (CCBs) exert potent antihypertensive effects. The CCB azelnidipine decreases heart rate by suppressing sympathetic nerve activity, which affects afferent and efferent arterioles in the glomeruli. We examined wheth... |
|
|
Azelnidipine, a new calcium channel blocker, promotes skin wound healing in diabetic rats.
J. Surg. Res. 169(1) , e101-7, (2011) Impaired wound healing in diabetes is associated with decreased nitric oxide (NO) bioavailability in wound tissue. We hypothesized azelnidipine (AZL), a new calcium channel blocker with antioxidant properties, would enhance wound healing in streptozotocin-ind... |
|
|
Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
Clin. Exp. Hypertens. 34(6) , 456-62, (2012) It has been demonstrated that the antihypertensive drugs with the antioxidant action on the brainstem inhibit the sympathetic activity and consequently decrease blood pressure and heart rate (HR) in hypertensive rats. Combination drugs of the angiotensin rece... |
|
|
The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Diab. Vasc. Dis. Res. 9(4) , 280-6, (2012) Angiotensin II receptor blockers (ARB) are often co-administered with a calcium channel blocker (CCB) for treating hypertension. In this open-label randomised study, untreated diabetic hypertensive patients were randomised to receive either olmesartan 20 mg/d... |